KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in...
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. ...
The premium-priced therapies used to treat ovarian cancer, such as Avastin (...
The premium-priced therapies used to treat ovarian cancer, such as Avastin (Roche/Genentech) and the PARP inhibitors Lynpar......
MARKET OUTLOOK The hepatocellular carcinoma (HCC) market in China is poised...
MARKET OUTLOOK The hepatocellular carcinoma (HCC) market in China is poised to experience a sudden explosion in market growth. Availability of existing systemic agents......
MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most...
MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of......
Market Outlook Clinical pathways, which establish optimal treatment...
Market Outlook Clinical pathways, which establish optimal treatment protocols for specific patient populations based on the best evidence, have become increasingly preva......
Market Outlook Immune checkpoint inhibitors are revolutionizing the...
Market Outlook Immune checkpoint inhibitors are revolutionizing the treatment algorithm for unresectable locally advanced or metastatic bladder cancer. Following the 201......
Market Outlook Therapeutic options for gastroesophageal cancer are limited;...
Market Outlook Therapeutic options for gastroesophageal cancer are limited; only two targeted agents are approved to treat gastric and ...
Market Outlook Malignant melanoma is the most aggressive and life-...
Market Outlook Malignant melanoma is the most aggressive and life-threatening skin cancer, the incidence of which continues to rise despite recent therapeutic advances.......
The ovarian cancer treatment algorithm is rapidly evolving. For decades,...
The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy has been the standard of care for ovarian cancer; however, treatment is changing to a targeted approach with......
Market Outlook Prostate cancer is the most common cancer among men in...
Market Outlook Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the main treatment for prostate cancer and are routin...
Although angiogenesis inhibitors are a mainstay in the treatment of renal cell...
Although angiogenesis inhibitors are a mainstay in the treatment of renal cell carcinoma, Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1 inhibit...
Coming Soon – June 2019 KEY BENEFITS AND USES Pinpoint current drug...
Coming Soon – June 2019 KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot...
Colorectal cancer is the third-most-common cancer globally and is associated...
Colorectal cancer is the third-most-common cancer globally and is associated with a five-year overall survival of 65.1%. Current treatment for metastatic colorectal cancer is dominated by ch...
The ovarian cancer treatment algorithm is rapidly evolving. For decades,...
The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy has been the standard of care for ovarian cancer; however, treatment is changing to a targeted approach with th......
Market Outlook Malignant melanoma is the most aggressive and life-threatening...
Market Outlook Malignant melanoma is the most aggressive and life-threatening skin cancer, the incidence of which continues to rise despite recent therapeutic advances. Owi......
Market Outlook Characterized by high incidence and long treatment durations,...
Market Outlook Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. ...
Market Outlook Therapeutic options for gastroesophageal cancer are limited;...
Market Outlook Therapeutic options for gastroesophageal cancer are limited; only two targeted agents are approved to treat gastric and ...
Although angiogenesis inhibitors are a mainstay in the treatment of renal cell...
Although angiogenesis inhibitors are a mainstay in the treatment of renal cell carcinoma, Bristol-Myers Squibb/Ono Pharmaceutical’s PD-1......
Market Outlook Immune checkpoint inhibitors are revolutionizing the treatment...
Market Outlook Immune checkpoint inhibitors are revolutionizing the treatment algorithm for unresectable locally advanced or metastatic bladder cancer. Following the 2016/7......
Market Outlook Prostate cancer is the most common cancer among men in developed...
Market Outlook Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the main treatment for prostate cancer and are routinely used......
